Atlas Trials

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Clinical trial NCT04213898 · UNKNOWN

Trial details

NCT number
NCT04213898
Sponsor
Henan Cancer Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Triple-negative Breast Cancer
Start date
2020-01-01
Primary completion
2021-01-01
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.